Parnell announced the acquisition of Noble Pharma LLC, a U.S.-based pharmaceutical manufacturer, according to the Securities Purchase Agreement dated November 26, 2025.

With this strategic acquisition, Parnell strengthens its U.S. operations and further advances its long-term commitment to delivering high‑quality products, reliable supply, and an enhanced level of support to its customers and distribution partners. Noble Pharma significantly enhances Parnell’s manufacturing capabilities, improves supply continuity, and supports continued growth across the company’s expanding product portfolio.

“Completing this acquisition marks an important milestone for Parnell,” said Brad McCarthy, the company’s Chief Executive Officer. “Noble Pharma’s operational excellence and established U.S. manufacturing footprint perfectly complement our mission to provide consistent supply, superior quality, and exceptional service to our partners and customers.”

The acquisition positions Parnell for continued expansion across the U.S. market, enabling the company to scale production, accelerate innovation, and better serve its growing customer base.